Funding and declaration of interest:
The study acquired funding from the European Union’s Horizon 2020
research and innovation programme CURE under grant agreement No 767015,
and the European FP7-Health programme PREDICTA under Grant agreement ID:
260895. CURE: “Constructing a ‘Eubiosis Reinstatement Therapy’ for
Asthma”. PREDICTA: “Post-infectious immune reprogramming and its
association with persistence and chronicity of respiratory allergic
diseases”. Disclaimer of EU responsibility: The content of this
publication reflects only the views of its authors. The European
Commission is not responsible for any use that may be made of the
information it contains.